Abstract
Excision repair cross complementation group 1 (ERCC1) is a promising biomarker in advanced non-small cell lung cancer (NSCLC). However, current evidence regarding the impact of ERCC1 on toxicity and quality of life (QOL) is limited.
Original language | English |
---|---|
Journal | European Journal of Cancer |
Volume | 46 |
Issue number | 9 |
Pages (from-to) | 1554-62 |
Number of pages | 9 |
ISSN | 0959-8049 |
DOIs | |
Publication status | Published - 1 Jun 2010 |